JPH0774218B2 - Benzopyranotriazole derivative - Google Patents
Benzopyranotriazole derivativeInfo
- Publication number
- JPH0774218B2 JPH0774218B2 JP62047392A JP4739287A JPH0774218B2 JP H0774218 B2 JPH0774218 B2 JP H0774218B2 JP 62047392 A JP62047392 A JP 62047392A JP 4739287 A JP4739287 A JP 4739287A JP H0774218 B2 JPH0774218 B2 JP H0774218B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- methoxybenzyl
- formula
- benzopyrano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BDWYNBWFUQKSSG-UHFFFAOYSA-N chromeno[2,3-d]triazole Chemical class O1C2=NN=NC2=CC2=CC=CC=C21 BDWYNBWFUQKSSG-UHFFFAOYSA-N 0.000 title 1
- -1 cyclodecyl group Chemical group 0.000 claims description 38
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 230000008602 contraction Effects 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BMGCDMZWMQQHMI-UHFFFAOYSA-N ethyl 2h-triazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNN=1 BMGCDMZWMQQHMI-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RUQFYHVGADABLL-UHFFFAOYSA-N 2-cyclopentyl-1-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1CCCC1 RUQFYHVGADABLL-UHFFFAOYSA-N 0.000 description 1
- PWPHFBYOLAZWLJ-UHFFFAOYSA-N 2h-chromeno[2,3-d]triazol-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1N=NN2 PWPHFBYOLAZWLJ-UHFFFAOYSA-N 0.000 description 1
- GTODOEDLCNTSLG-UHFFFAOYSA-N 2h-triazole-4-carboxylic acid Chemical compound OC(=O)C1=CNN=N1 GTODOEDLCNTSLG-UHFFFAOYSA-N 0.000 description 1
- NHUBTIVSPMHGNM-UHFFFAOYSA-N 7-[2-(3-chlorophenyl)ethyl]-2h-chromeno[2,3-d]triazol-9-one Chemical compound ClC1=CC=CC(CCC=2C=C3C(=O)C4=NNN=C4OC3=CC=2)=C1 NHUBTIVSPMHGNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 〈産業上の利用分野〉 本発明は一般式 (式中、Rはシクロブチル基、シクロペンチル基、シク
ロヘキシル基、シクロヘプチル基、シクロオクチル基、
シクロノニル基、シクロデシル基、シクロドデシル基又
はフェニル基を意味し、該シクロブチル基、シクロペン
チル基、シクロヘキシル基、シクロヘプチル基、シクロ
オクチル基、シクロノニル基、シクロデシル基、シクロ
ドデシル基及びフェニル基はハロゲン原子を一つ以上有
してもよく、Xはメチレン、エチレン、プロピレン、ブ
チレンを意味する)で示される化合物及びその塩に関す
る。DETAILED DESCRIPTION OF THE INVENTION <Industrial field of application> (In the formula, R is a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group,
A cyclononyl group, a cyclodecyl group, a cyclododecyl group or a phenyl group means a cyclohexyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, a cyclodecyl group, a cyclododecyl group or a phenyl group and a halogen atom. One or more, X means methylene, ethylene, propylene, butylene) and a salt thereof.
式(I)の化合物は優れた抗アレルギー作用を有し、医
薬として有用である。The compound of formula (I) has an excellent antiallergic action and is useful as a medicine.
〈従来技術〉 近年、免疫反応等の種々の刺激により生成し、アレルギ
ー反応を引き起こすケミカルメディエーターの一つとし
てロイコトリエンD4(以下、LTD4と称する。)が重要
視されてきており、本LTD4に対する拮抗作用は抗アレル
ギー作用の指標の一つとしてますます重要であると考え
られてきた。<Prior Art> In recent years, leukotriene D 4 (hereinafter referred to as LTD 4 ) has been regarded as important as one of the chemical mediators that are generated by various stimuli such as immune reaction and cause an allergic reaction, and this LTD 4 It has been considered that the antagonism against glycerin is increasingly important as one of the indicators of the antiallergic effect.
又、[1]ベンゾピラノ[2,3−d]−1,2,3−トリアゾ
ール−9(1H)−オンに低級アルキル基が置換した化合
物が特開昭55-19292号公報及びジャーナル オブ メデ
ィシナル ケミストリイー26巻、251-254頁(1983)に
開示されている。本化合物については同種受動感作ラッ
ト皮膚アナフイラキシーの抑制作用が開示されている
が、前記LTD4拮抗作用の開示はない。Further, a compound obtained by substituting a lower alkyl group for [1] benzopyrano [2,3-d] -1,2,3-triazol-9 (1H) -one is disclosed in JP-A-55-19292 and Journal of Medicinal Chemistry. E 26, 251-254 (1983). Although this compound has been disclosed to suppress the skin anaphylaxis of allogeneic passively sensitized rats, it does not disclose the aforementioned LTD 4 antagonism.
〈発明が解決しようとする問題点〉 本発明者等は優れたLTD4拮抗作用を有する化合物を見い
出すべく鋭意検討した結果本発明を完成した。<Problems to be Solved by the Invention> The present inventors have completed the present invention as a result of extensive studies to find a compound having an excellent LTD 4 antagonistic action.
〈発明の構成〉 本発明は式(I)の化合物及びその塩に関する。The present invention relates to compounds of formula (I) and salts thereof.
式(I)においてアルキル基としてはメチル、エチル、
プロピル、イソプロピル、ブチル、第三級ブチル等をあ
げることができる。ハロゲン原子としてはフッ素、塩
素、臭素、ヨウ素をあげることができる。ハロゲノアル
キル基とは前記ハロゲン原子が一つ以上アルキル基に置
換したものを意味し、その例としてはハロゲノメチル、
ハロゲノエチル、ハロゲノブチル、ジハロゲノメチル、
ジハロゲノブチル、トリハロゲノメチル等をあげること
ができる。シクロアルキル基としてはシクロブチル、シ
クロペンチル、シクロヘキシル、シクロヘプチル、シク
ロオクチル、シクロノニル、シクロデシル、シクロドデ
シル等をあげることができる。シクロアルケニル基とし
てはシクロブテニル、シクロヘプテニル、シクロヘキセ
ニル、シクロオクテニル、シクロデセニル、シクロドデ
セニル等をあげることができる。アルキレン基とはアル
キル基が置換してもよいメチレン又はポリメチレンを意
味し、その例としてはメチレン、エチレン、プロピレ
ン、ブチレン等をあげることができる。アルケニレンと
してはビニレン、プロペニレン、ブテニレン、1−ペン
テニレン、2−メチル−1−ブテニレン、2−メチル−
2−ブテニレン等をあげることができる。In formula (I), the alkyl group is methyl, ethyl,
Examples thereof include propyl, isopropyl, butyl, tertiary butyl and the like. Examples of the halogen atom include fluorine, chlorine, bromine and iodine. A halogenoalkyl group means one in which one or more of the above halogen atoms are substituted with an alkyl group, examples of which include halogenomethyl,
Halogenoethyl, halogenobutyl, dihalogenomethyl,
Examples thereof include dihalogenobutyl and trihalogenomethyl. Examples of the cycloalkyl group include cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclododecyl and the like. Examples of the cycloalkenyl group include cyclobutenyl, cycloheptenyl, cyclohexenyl, cyclooctenyl, cyclodecenyl, cyclododecenyl and the like. The alkylene group means methylene or polymethylene which may be substituted with an alkyl group, and examples thereof include methylene, ethylene, propylene, butylene and the like. As alkenylene, vinylene, propenylene, butenylene, 1-pentenylene, 2-methyl-1-butenylene, 2-methyl-
2-butenylene etc. can be mentioned.
式(I)の化合物の塩としてはナトリウム、カリウム等
のアルカリ金属、カルシウム等のアルカリ土類金属又は
アンモニア、トリス(ヒドロキシメチル)アミノメタ
ン、N−メチルグルカミン等のアミン類との塩等を例示
することができる。Examples of the salt of the compound of the formula (I) include salts with alkali metals such as sodium and potassium, alkaline earth metals such as calcium or ammonia, amines such as tris (hydroxymethyl) aminomethane and N-methylglucamine. It can be illustrated.
式(I)の化合物は便宜的に1H−9−オキソ体として表
現したが、本化合物は下記の互変異性体(I′)、
(I″)及び(I)を含んでいる。これら互変異性体
も本発明に含まれる。Although the compound of formula (I) is represented as a 1H-9-oxo compound for convenience, this compound is represented by the following tautomer (I ′),
It includes (I ″) and (I). These tautomers are also included in the present invention.
更に式(I)の化合物についてはその部分構造R及びX
に由来する各種異性体が存在する場合があり、これらの
各種異性体及びそれらの混合物も本発明に含まれる。 Further, for the compound of formula (I), the partial structures R and X
There may be various isomers derived from the above, and these various isomers and mixtures thereof are also included in the present invention.
式(I)で表わされる化合物は下記反応式に従って製造
することが出来る。The compound represented by the formula (I) can be produced according to the following reaction formula.
(式中R及びXは前記に同じである。) 即ち式(II)の化合物を溶媒の存在下又は非存在下、酸
と処理することにより式(I)の化合物を製造すること
が出来る。反応は通常氷冷下〜室温で30分間〜数日間行
われる。この際アニソールを添加することにより反応は
より円滑に進行することができる。好適な酸としては、
トリフルオロ酢酸を挙げることができる。 (In the formula, R and X are the same as above.) That is, the compound of formula (I) can be produced by treating the compound of formula (II) with an acid in the presence or absence of a solvent. The reaction is usually performed under ice cooling to room temperature for 30 minutes to several days. At this time, the reaction can proceed more smoothly by adding anisole. Suitable acids include
Mention may be made of trifluoroacetic acid.
上述の製法で用いられる原料化合物(II)は新規化合物
であり、下記の方法で製造することができる。The starting compound (II) used in the above production method is a novel compound and can be produced by the following method.
(式中R及びXは前記に同じである。) 上記反応工程について説明する。 (In formula, R and X are the same as the above.) The said reaction process is demonstrated.
式(III)の化合物と式(IV)の化合物を炭酸カリウ
ム、水素化ナトリウム等の塩基と共に、ジメチルホルム
アミド、ジメトキシエタン等の反応に関与しない溶媒中
反応させることにより式(V)の化合物を製造すること
ができる。反応は通常100〜200℃で1時間〜数日間行わ
れる。A compound of formula (V) is produced by reacting a compound of formula (III) with a compound of formula (IV) together with a base such as potassium carbonate or sodium hydride in a solvent such as dimethylformamide or dimethoxyethane which does not participate in the reaction. can do. The reaction is usually carried out at 100 to 200 ° C. for 1 hour to several days.
式(V)の化合物を水酸化ナトリウム、水酸化カリウム
等と反応に関与しない溶媒例えば含水アルコール中で反
応させることにより式(VI)の化合物を製造することが
できる。反応は通常室温で30分間〜5時間行われる。The compound of formula (VI) can be produced by reacting the compound of formula (V) with sodium hydroxide, potassium hydroxide or the like in a solvent that does not participate in the reaction, for example, hydrous alcohol. The reaction is usually performed at room temperature for 30 minutes to 5 hours.
式(VI)の化合物をジクロロメタン等の反応に関与しな
い溶媒中クロル化剤と室温で30分間〜2時間反応させる
ことにより式(VII)の化合物を製造することができ
る。好適なクロル化剤としてはオキザリルクロリドをあ
げることができる。The compound of formula (VII) can be produced by reacting the compound of formula (VI) with a chlorinating agent in a solvent that does not participate in the reaction such as dichloromethane at room temperature for 30 minutes to 2 hours. A suitable chlorinating agent may be oxalyl chloride.
式(VII)の化合物を通常のフリーデルクラフト反応の
条件下処理することにより式(II)の化合物を製造する
ことができる。反応は通常ジクロロメタン等の反応に関
与しない溶媒中塩化アルミニウムの存在下−5℃〜室温
で0.5〜3時間行われる。The compound of formula (II) can be produced by treating the compound of formula (VII) under the conditions of a usual Friedel-Crafts reaction. The reaction is usually carried out in the presence of aluminum chloride in a solvent such as dichloromethane which does not participate in the reaction at -5 ° C to room temperature for 0.5 to 3 hours.
〈発明の効果〉 本発明化合物は優れたLTD4拮抗作用を有するものであ
る。<Effects of the Invention> The compounds of the present invention have excellent LTD 4 antagonistic activity.
従って本発明化合物は気管支喘息、アレルギー性胃腸障
害、アレルギー性結膜炎、アレルギー性鼻炎、枯草熱、
蕁麻疹、炎症性疾患等の治療又は予防に有効である。Therefore, the compound of the present invention is applicable to bronchial asthma, allergic gastrointestinal disorders, allergic conjunctivitis, allergic rhinitis, hay fever,
It is effective for treating or preventing urticaria, inflammatory diseases and the like.
本発明を以下の実施例、参考例及び試験例により説明す
る。The present invention will be described with reference to the following examples, reference examples and test examples.
実施例1 7−[2−(3−クロロフェニル)エチル]−[1]ベ
ンゾピラノ[2,3−d]−1,2,3−トリアゾール−9(1
H)−オン トリフルオロ酢酸30mlに7−[2−(3−クロロフェニ
ル)エチル]−3−(4−メトキシベンジル)−[1]
ベンゾピラノ[2,3−d]−1,2,3−トリアゾール−9
(3H)−オン3.45g及びアニソール8.18gを加え、室温で
22.5時間攪拌した。反応混合物を氷水200ml中に注ぎク
ロロホルムで抽出した。クロロホルム層を濃縮しメタノ
ールを加え不溶物を濾取した。クロロホルム−エタノー
ルより再結晶し表題化合物を融点222〜223℃の無色プリ
ズム晶として1.12g得た。Example 1 7- [2- (3-chlorophenyl) ethyl]-[1] benzopyrano [2,3-d] -1,2,3-triazole-9 (1
H) -one 7- [2- (3-chlorophenyl) ethyl] -3- (4-methoxybenzyl)-[1] in 30 ml of trifluoroacetic acid.
Benzopyrano [2,3-d] -1,2,3-triazole-9
Add (3H) -one 3.45g and anisole 8.18g, at room temperature
It was stirred for 22.5 hours. The reaction mixture was poured into 200 ml of ice water and extracted with chloroform. The chloroform layer was concentrated, methanol was added, and the insoluble material was collected by filtration. Recrystallization from chloroform-ethanol gave 1.12 g of the title compound as colorless prism crystals with a melting point of 222-223 ° C.
実施例1と同様にして式(I)で表わされる実施例2〜
6の化合物を合成した。Example 2 represented by the formula (I) in the same manner as in Example 1
Compound 6 was synthesized.
実施例7 7−(2−シクロヘキシルエチル)−[1]ベンゾピラ
ノ[2,3−d]−1,2,3−トリアゾール−9(1H)−オン 1) 7−(2−シクロヘキシルエチル)−3−(4−
メトキシベンジル)−[1]−ベンゾピラノ[2,3−
d]−1,2,3−トリアゾール−9(3H)−オン ジクロロメタン250mlに5−[4−(2−シクロヘキシ
ルエチル)フェノキシ]−1−(4−メトキシベンジ
ル)−1H−1,2,3−トリアゾール−4−カルボン酸26.0
g、オキザリルクロリド15.16g及びジメチルホルムアミ
ド1滴を加え室温で1時間攪拌後溶媒及び低沸点物を減
圧留去した。残留物をジクロロメタン250mlに溶かし、
0℃以下を保ち塩化アルミニウム24.0gを20分間で加え
た。−5〜0℃で2時間攪拌後、塩酸−氷にあけジクロ
ロメタンで抽出した。抽出液を水洗乾燥し、溶媒を留去
し、表題化合物を固体として得た。 Example 7 7- (2-Cyclohexylethyl)-[1] benzopyrano [2,3-d] -1,2,3-triazol-9 (1H) -one 1) 7- (2-Cyclohexylethyl) -3 -(4-
Methoxybenzyl)-[1] -benzopyrano [2,3-
d] -1,2,3-triazol-9 (3H) -one 5- [4- (2-cyclohexylethyl) phenoxy] -1- (4-methoxybenzyl) -1H-1,2,3 in 250 ml of dichloromethane. -Triazole-4-carboxylic acid 26.0
g, 15.16 g of oxalyl chloride and 1 drop of dimethylformamide were added, and the mixture was stirred at room temperature for 1 hour, and then the solvent and low-boiling substances were distilled off under reduced pressure. Dissolve the residue in 250 ml of dichloromethane,
While keeping the temperature below 0 ° C, 24.0 g of aluminum chloride was added over 20 minutes. After stirring at -5 to 0 ° C for 2 hours, the mixture was poured into hydrochloric acid-ice and extracted with dichloromethane. The extract was washed with water and dried, and the solvent was evaporated to give the title compound as a solid.
2) 7−(2−シクロヘキシルエチル)−[1]ベン
ゾピラノ[2,3−d]−1,2,3−トリアゾール−9(1H)
−オン上記の7−(2−シクロヘキシルエチル)−3−
(4−メトキシベンジル)−[1]ベンゾピラノ[2,3
−d]−1,2,3−トリアゾール−9(3H)−オン及びア
ニソール65gをトリフルオロ酢酸140mlに加え室温で3日
放置した。反応液を減圧濃縮後残留物をシリカゲルクロ
マトグラフィーにふし、エタノールより再結晶し表題化
合物5.61gを得た。2) 7- (2-Cyclohexylethyl)-[1] benzopyrano [2,3-d] -1,2,3-triazole-9 (1H)
-One 7- (2-cyclohexylethyl) -3- as above
(4-Methoxybenzyl)-[1] benzopyrano [2,3
-D] -1,2,3-triazol-9 (3H) -one and 65 g of anisole were added to 140 ml of trifluoroacetic acid and left at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure and the residue was chromatographed on silica gel and recrystallized from ethanol to give the title compound (5.61 g).
融点 183〜184℃ 実施例に記した式(I)の化合物の元素分析値、核磁気
共鳴スペクトル及び赤外吸収スペクトルを下表に示す。Melting point 183 to 184 ° C. Elemental analysis values, nuclear magnetic resonance spectra and infrared absorption spectra of the compounds of formula (I) described in the examples are shown in the table below.
実施例で用いた式(V)、(VI)、(VII)及び(II)
の原料化合物の合成法を参考例として以下に述べる。 Formulas (V), (VI), (VII) and (II) used in the examples
The method of synthesizing the starting material compound will be described below as a reference example.
参考例1 7−[2−(3−クロロフェニル)エチル]−3−(4
−メトキシベンジル)−[1]ベンゾピラノ[2,3−
d]−1,2,3−トリアゾール−9(3H)−オン 1) 5−[4−[2−(3−クロロフェニル)エチ
ル]フェノキシ]−1−(4−メトキシベンジル)−1H
−1,2,3−トリアゾール−4−カルボン酸 4−[2−(3−クロロフェニル)エチル]フェノール
80g及び5−クロロ−1−(4−メトキシベンジル)−1
H−1,2,3−トリアゾール−4−カルボン酸エチルエステ
ル100gをジメチルホルムアミド1000mlに溶解し、炭酸カ
リウム100gを加え120-140℃で3日間加熱攪拌した。反
応液を氷−濃塩酸にあけエーテルで抽出した。エーテル
層を乾燥後溶媒を留去した。残留物に水酸化カリウム30
g、水30ml及びエタノール1500mlを加え室温で1時間攪
拌した。析出した結晶を濾取し、エタノール、エーテル
で順次洗った後酢酸エチル−水に懸濁させ、濃塩酸で酸
性とした。酢酸エチル層を取り乾燥後溶媒を留去した。
残留物をエーテル−石油エーテルより再結晶し、表題化
合物105.9gを得た。融点127-130℃ 元素分析 C25H22ClN3O4として 計算値 C 64.73 H 4.78 N 9.06 実測値 C 65.04 H 4.97 N 9.20 2) 7−[2−(3−クロロフェニル)エチル]−3
−(4−メトキシベンジル)−[1]ベンゾピラノ[2,
3−d]−1,2,3−トリアゾール−9(3H)−オン ジクロロメタン500mlに5−[4−[2−(3−クロロ
フェニル)エチル]フェノキシ]−1−(4−メトキシ
ベンジル)−1H−1,2,3−トリアゾール−4−カルボン
酸60.0gを溶かし、オキザリルクロリド33gを室温で滴下
した。滴下後ジメチルホルムアミド1滴を加え室温で1
時間攪拌した。溶媒及び低沸点物を減圧留去した。残留
物をジクロロメタン1000mlに溶かし、0℃以下に保ちつ
つ塩化アルミニウム53gを加え−5〜0℃で5.5時間攪拌
した。反応混合物を氷−濃塩酸にあけクロロホルムで抽
出した。クロロホルム層を水洗乾燥後溶媒を留去した。
残留物をクロロホルム−メタノールで結晶化させ表題化
合物23.7gを得た。Reference Example 1 7- [2- (3-chlorophenyl) ethyl] -3- (4
-Methoxybenzyl)-[1] benzopyrano [2,3-
d] -1,2,3-Triazol-9 (3H) -one 1) 5- [4- [2- (3-chlorophenyl) ethyl] phenoxy] -1- (4-methoxybenzyl) -1H
-1,2,3-triazole-4-carboxylic acid 4- [2- (3-chlorophenyl) ethyl] phenol
80 g and 5-chloro-1- (4-methoxybenzyl) -1
100 g of H-1,2,3-triazole-4-carboxylic acid ethyl ester was dissolved in 1000 ml of dimethylformamide, 100 g of potassium carbonate was added, and the mixture was heated and stirred at 120-140 ° C for 3 days. The reaction solution was poured into ice-concentrated hydrochloric acid and extracted with ether. After drying the ether layer, the solvent was distilled off. Residue potassium hydroxide 30
g, 30 ml of water and 1500 ml of ethanol were added, and the mixture was stirred at room temperature for 1 hour. The precipitated crystals were collected by filtration, washed successively with ethanol and ether, suspended in ethyl acetate-water, and acidified with concentrated hydrochloric acid. The ethyl acetate layer was taken and dried, and then the solvent was distilled off.
The residue was recrystallized from ether-petroleum ether to obtain 105.9 g of the title compound. Melting point 127-130 ° C Elemental analysis Calculated as C 25 H 22 ClN 3 O 4 C 64.73 H 4.78 N 9.06 Found C 65.04 H 4.97 N 9.20 2) 7- [2- (3-chlorophenyl) ethyl] -3
-(4-Methoxybenzyl)-[1] benzopyrano [2,
3-d] -1,2,3-triazol-9 (3H) -one 5- [4- [2- (3-chlorophenyl) ethyl] phenoxy] -1- (4-methoxybenzyl) -1H in 500 ml of dichloromethane. 60.0 g of -1,2,3-triazole-4-carboxylic acid was dissolved, and 33 g of oxalyl chloride was added dropwise at room temperature. After the addition, add 1 drop of dimethylformamide and add 1 at room temperature.
Stir for hours. The solvent and low boiling point substances were distilled off under reduced pressure. The residue was dissolved in 1000 ml of dichloromethane, 53 g of aluminum chloride was added while keeping the temperature below 0 ° C, and the mixture was stirred at -5 to 0 ° C for 5.5 hours. The reaction mixture was poured into ice-concentrated hydrochloric acid and extracted with chloroform. The chloroform layer was washed with water and dried, and the solvent was distilled off.
The residue was crystallized from chloroform-methanol to obtain the title compound (23.7 g).
融点 178-179℃ 元素分析 C25H20ClN3O3として 計算値 C 67.34 H 4.52 N 9.42 実測値 C 67.36 H 4.57 N 9.16 参考例2 3−(4−メトキシベンジル)−5−(2−フェニルエ
チル)−[1]ベンゾピラノ[2,3−d]−1,2,3−トリ
アゾール−9(3H)−オン 2−(2−フェニルエチル)フェノール及び5−クロロ
−1−(4−メトキシベンジル)−1H−1,2,3−トリア
ゾール−4−カルボン酸エチルエステルを参考例1と同
様にして反応させ表題化合物を得た。融点不鮮明 核磁気共鳴スペクトル(DMSO−d6)δ値:2.90-3.05(2
H,m),3.15-3.30(2H,m),5.74(2H,s),6.87(2H,d),
7.55(8H,m),7.7(1H,d),8.1(1H,d) 参考例3 3−(4−メトキシベンジル)−8−(2−フェニルエ
チル)−[1]ベンゾピラノ[2,3−d]−1,2,3−トリ
アゾール−9(3H)−オン及び3−(4−メトキシベン
ジル)−6−(2−フェニルエチル)−[1]ベンゾピ
ラノ[2,3−d]−1,2,3−トリアゾール−9(3H)−オ
ン 3−(2−フェニルエチル)フェノール及び5−クロロ
−1−(4−メトキシベンジル)−1H−1,2,3−トリア
ゾール−4−カルボン酸エチルエステルを参考例1の
1)と同様に反応させて5−[3−(2−フェニルエチ
ル)フェノキシ]−1−(4−メトキシベンジル)−1H
−1,2,3−トリアゾール−4−カルボン酸を得た。Melting point 178-179 ° C Elemental analysis Calculated as C 25 H 20 ClN 3 O 3 C 67.34 H 4.52 N 9.42 Measured value C 67.36 H 4.57 N 9.16 Reference example 2 3- (4-methoxybenzyl) -5- (2-phenyl) Ethyl)-[1] benzopyrano [2,3-d] -1,2,3-triazol-9 (3H) -one 2- (2-phenylethyl) phenol and 5-chloro-1- (4-methoxybenzyl) ) -1H-1,2,3-triazole-4-carboxylic acid ethyl ester was reacted in the same manner as in Reference Example 1 to obtain the title compound. Melting point unclear Nuclear magnetic resonance spectrum (DMSO-d 6 ) δ value: 2.90-3.05 (2
H, m), 3.15-3.30 (2H, m), 5.74 (2H, s), 6.87 (2H, d),
7.55 (8H, m), 7.7 (1H, d), 8.1 (1H, d) Reference Example 3 3- (4-methoxybenzyl) -8- (2-phenylethyl)-[1] benzopyrano [2,3- d] -1,2,3-triazol-9 (3H) -one and 3- (4-methoxybenzyl) -6- (2-phenylethyl)-[1] benzopyrano [2,3-d] -1, 2,3-Triazol-9 (3H) -one 3- (2-phenylethyl) phenol and 5-chloro-1- (4-methoxybenzyl) -1H-1,2,3-triazole-4-carboxylate ethyl The ester was reacted in the same manner as in 1) of Reference Example 1 to give 5- [3- (2-phenylethyl) phenoxy] -1- (4-methoxybenzyl) -1H.
-1,2,3-Triazole-4-carboxylic acid was obtained.
融点 112-113℃(分解) ジクロロメタン150mlに5−[3−(2−フェニルエチ
ル)フェノキシ]−1−(4−メトキシベンジル)−1H
−1,2,3−トリアゾール−4−カルボン酸19.1g及びオキ
ザリルクロリド11.29gを溶かし、ジメチルホルムアミド
1滴を加え、室温で1時間攪拌後、溶媒及び低沸点物を
減圧留去した。残留物をジクロロメタン80mlに溶かし、
氷冷して塩化アルミニウム17.80gを加え、2時間攪拌し
た。反応混合物を氷−濃塩酸にあけクロロホルムで抽出
した。クロロホルム層を乾燥後溶媒を留去した。残留物
をシリカゲルクロマトグラフィーに付し粗製の3−(4
−メトキシベンジル)−8−(2−フェニルエチル)−
[1]ベンゾピラノ[2,3−d]−1,2,3−トリアゾール
−9(3H)−オン(粗製物I)及び3−(4−メトキシ
ベンジル)−6−(2−フェニルエチル)−[1]ベン
ゾピラノ[2,3−d]−1,2,3−トリアゾール−9(3H)
−オン(粗製物II)を得た。粗製物Iを酢酸エチルより
再結晶し、3−(4−メトキシベンジル)−8−(2−
フェニルエチル)−[1]ベンゾピラノ[2,3−d]−
1,2,3−トリアゾール−9(3H)−オン1.72gを得た。Melting point 112-113 ° C (decomposition) 5- [3- (2-phenylethyl) phenoxy] -1- (4-methoxybenzyl) -1H in 150 ml of dichloromethane
1,1,2,3-Triazole-4-carboxylic acid (19.1 g) and oxalyl chloride (11.29 g) were dissolved, dimethylformamide (1 drop) was added, the mixture was stirred at room temperature for 1 hr, and the solvent and low-boiling substances were distilled off under reduced pressure. Dissolve the residue in 80 ml of dichloromethane,
After cooling with ice, 17.80 g of aluminum chloride was added, and the mixture was stirred for 2 hours. The reaction mixture was poured into ice-concentrated hydrochloric acid and extracted with chloroform. After the chloroform layer was dried, the solvent was distilled off. The residue was chromatographed on silica gel to give crude 3- (4
-Methoxybenzyl) -8- (2-phenylethyl)-
[1] Benzopyrano [2,3-d] -1,2,3-triazol-9 (3H) -one (crude I) and 3- (4-methoxybenzyl) -6- (2-phenylethyl)- [1] Benzopyrano [2,3-d] -1,2,3-triazole-9 (3H)
-ON (crude II) was obtained. The crude product I was recrystallized from ethyl acetate to give 3- (4-methoxybenzyl) -8- (2-
Phenylethyl)-[1] benzopyrano [2,3-d]-
1.72 g of 1,2,3-triazol-9 (3H) -one were obtained.
融点〜186℃(不鮮明) 元素分析 C25H21N3O2として 計算値 C 72.98 H 5.14 N 10.12 実測値 C 73.14 H 5.31 N 9.93 粗製物IIをメタノールより再結晶し、3−(4−メトキ
シベンジル)−6−(2−フェニルエチル)−[1]ベ
ンゾピラノ[2,3−d]−1,2,3−トリアゾール−9(3
H)−オン4.46gを得た。融点173-174.5℃ 元素分析 C25H21N3O2として 計算値 C 72.98 H 5.14 N 10.12 実測値 C 73.36 H 5.29 N 10.07 参考例4 3−(4−メトキシベンジル)−7−(2−フェニルエ
チル)−[1]ベンゾピラノ[2,3−d]−1,2,3−トリ
アゾール−9(3H)−オン 4−(2−フェニルエチル)フェノール及び5−クロロ
−1−(4−メトキシベンジル)−1H−1,2,3−トリア
ゾール−4−カルボン酸エチルエステルを参考例1と同
様に反応させて表題化合物を得た。Melting point to 186 ° C (unclear) Elemental analysis Calculated as C 25 H 21 N 3 O 2 C 72.98 H 5.14 N 10.12 Found C 73.14 H 5.31 N 9.93 Crude product II was recrystallized from methanol to give 3- (4-methoxy). Benzyl) -6- (2-phenylethyl)-[1] benzopyrano [2,3-d] -1,2,3-triazole-9 (3
H) -one yielded 4.46 g. Melting point 173-174.5 ° C Elemental analysis Calculated value as C 25 H 21 N 3 O 2 C 72.98 H 5.14 N 10.12 Measured value C 73.36 H 5.29 N 10.07 Reference example 4 3- (4-methoxybenzyl) -7- (2-phenyl Ethyl)-[1] benzopyrano [2,3-d] -1,2,3-triazol-9 (3H) -one 4- (2-phenylethyl) phenol and 5-chloro-1- (4-methoxybenzyl) ) -1H-1,2,3-triazole-4-carboxylic acid ethyl ester was reacted in the same manner as in Reference Example 1 to obtain the title compound.
融点〜170℃(不鮮明) 核磁気共鳴スペクトル(CDCl3)δ値: 3.01(4H,bs),3.79(3H,s),5.61(2H,s),6.85-7.45
(11H,m),8.26(1H,bs) 参考例5 7−(2−シクロペンチルエチル)−3−(4−メトキ
シベンジル)−[1]ベンゾピラノ[2,3−d]−1,2,3
−トリアゾール−9(3H)−オン 1) 4−(2−シクロペンチルエチル)メトキシベン
ゼン ジエチレングリコールモノエチルエーテル150mlに2−
シクロペンチル−1−(4−メトキシフェニル)エタノ
ン35.9gとヒドラジンヒドラート30mlを加え180℃に加熱
した。次いで40%水酸化ナトリウム水溶液30ml及び水30
mlを加え加熱した。Melting point ~ 170 ° C (unclear) Nuclear magnetic resonance spectrum (CDCl 3 ) δ value: 3.01 (4H, bs), 3.79 (3H, s), 5.61 (2H, s), 6.85-7.45
(11H, m), 8.26 (1H, bs) Reference Example 5 7- (2-Cyclopentylethyl) -3- (4-methoxybenzyl)-[1] benzopyrano [2,3-d] -1,2,3
-Triazol-9 (3H) -one 1) 4- (2-cyclopentylethyl) methoxybenzene 2-ethylene in 150 ml diethylene glycol monoethyl ether
35.9 g of cyclopentyl-1- (4-methoxyphenyl) ethanone and 30 ml of hydrazine hydrate were added and heated to 180 ° C. Next, 30 ml of 40% sodium hydroxide aqueous solution and water 30
ml was added and heated.
約100mlの留出物を除き、水2mlを加え5日間加熱還流後
水に注ぎ石油エーテルで抽出した。抽出液を水洗乾燥
し、溶媒を留去後一部の析出物を濾別し表題化合物5.4g
を液体として得た。About 100 ml of distillate was removed, 2 ml of water was added, and the mixture was heated under reflux for 5 days, poured into water and extracted with petroleum ether. The extract was washed with water and dried, the solvent was distilled off, and some precipitates were filtered off to give the title compound (5.4 g)
Was obtained as a liquid.
2) 4−(2−シクロペンチルエチル)フェノール ジクロロメタン50mlを氷冷し、塩化アルミニウム7.75g
を加え、次いでジメチルスルフィッド7.21gを加えた。
これに4−(2−シクロペンチルエチル)メトキシベン
ゼン5.4gのジクロロメタン20ml溶液を滴下した。室温で
18時間攪拌後、塩酸−氷に注ぎジクロロメタンで抽出し
た。抽出液を水洗乾燥後、溶媒を留去し表題化合物4.41
gを無色液体として得た。2) 4- (2-cyclopentylethyl) phenol 50 ml of dichloromethane is cooled with ice, and aluminum chloride is 7.75 g.
Was added, followed by 7.21 g of dimethyl sulfide.
A solution of 5.4 g of 4- (2-cyclopentylethyl) methoxybenzene in 20 ml of dichloromethane was added dropwise thereto. At room temperature
After stirring for 18 hours, the mixture was poured into hydrochloric acid-ice and extracted with dichloromethane. The extract was washed with water and dried, and the solvent was evaporated to give the title compound 4.41
g was obtained as a colorless liquid.
核磁気共鳴スペクトル(CDCl3)δ値: 0.9-2.0(11H,m),2.46-2.63(2H,m),4.60(1H,bs)6.
72(2H,d),7.03(2H,d) 3) 7−(2−シクロペンチルエチル)−3−(4−
メトキシベンジル)−[1]ベンゾピラノ[2,3−d]
−1,2,3−トリアゾール−9(3H)−オン 4−(2−シクロペンチルエチル)フェノール及び5−
クロロ−1−(4−メトキシベンジル)−1H−1,2,3−
トリアゾール−4−カルボン酸エチルエステルを参考例
1と同様に反応させて表題化合物を得た。Nuclear magnetic resonance spectrum (CDCl 3 ) δ value: 0.9-2.0 (11H, m), 2.46-2.63 (2H, m), 4.60 (1H, bs) 6.
72 (2H, d), 7.03 (2H, d) 3) 7- (2-cyclopentylethyl) -3- (4-
Methoxybenzyl)-[1] benzopyrano [2,3-d]
-1,2,3-triazol-9 (3H) -one 4- (2-cyclopentylethyl) phenol and 5-
Chloro-1- (4-methoxybenzyl) -1H-1,2,3-
The title compound was obtained by reacting triazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 1.
融点 177-178℃ 元素分析 C24H25N3O3として 計算値 C 71.44 H 6.25 N 10.41 実測値 C 71.35 H 6.25 N 10.41 参考例6 5−[4−(2−シクロヘキシルエチル)フェノキシ]
−1−(4−メトキシベンジル)−1H−1,2,3−トリア
ゾール−4−カルボン酸 4−(2−シクロヘキシルエチル)フェノール及び5−
クロロ−1−(4−メトキシベンジル)−1H−1,2,3−
トリアゾール−4−カルボン酸エチルエステルを参考例
1の1)と同様に反応させて表題化合物を得た。Melting point 177-178 ° C Elemental analysis Calculated value as C 24 H 25 N 3 O 3 C 71.44 H 6.25 N 10.41 Measured value C 71.35 H 6.25 N 10.41 Reference Example 6 5- [4- (2-cyclohexylethyl) phenoxy]
-1- (4-Methoxybenzyl) -1H-1,2,3-triazole-4-carboxylic acid 4- (2-cyclohexylethyl) phenol and 5-
Chloro-1- (4-methoxybenzyl) -1H-1,2,3-
The title compound was obtained by reacting triazole-4-carboxylic acid ethyl ester in the same manner as in 1) of Reference Example 1.
融点 135℃(分解) 元素分析 C25H29N3O4として 計算値 C 68.95 H 6.71 N 9.65 実測値 C 68.89 H 6.85 N 9.62 試験例 LTD4拮抗作用試験 体重300〜600gの雄性モルモットを放血致死させた後、
回腸を摘出し長さ約2cmの標本を作成した。Melting point 135 ° C (decomposition) Elemental analysis Calculated value as C 25 H 29 N 3 O 4 C 68.95 H 6.71 N 9.65 Measured value C 68.89 H 6.85 N 9.62 Test example LTD 4 Antagonism test Male guinea pigs weighing 300 to 600 g were lethal. After letting
The ileum was removed to prepare a specimen with a length of about 2 cm.
この回腸標本を95%O2−5%CO2の混合ガスを通気した
Tyrode液5ml(30±1℃)を満たしたMagnus槽中に懸垂
した。回腸の収縮は0.6gの加重下で等張性トランスジュ
ーサーによりレコーダーに記録した。This ileum sample was aerated with a mixed gas of 95% O 2 -5% CO 2 .
It was suspended in a Magnus tank filled with 5 ml of Tyrode solution (30 ± 1 ° C). Ileal contractions were recorded on a recorder with an isotonic transducer under a load of 0.6 g.
安定した収縮反応が生じることを確認した後、LTD4(3.
0ng/ml)を加え収縮反応を惹起させた。薬物の前処置時
間は1分とし、その時生じた収縮の程度を被験薬物無添
加時の収縮と比較し、その抑制率から50%抑制用量(IC
50値)を算出した。本発明化合物のLTD4拮抗作用を下表
に示す。After confirming that a stable contraction reaction occurs, LTD 4 (3.
0 ng / ml) was added to induce a contraction reaction. The pretreatment time of the drug was set to 1 minute, and the degree of contraction that occurred at that time was compared with the contraction without addition of the test drug.
50 values) were calculated. The following table shows the LTD 4 antagonism of the compound of the present invention.
Claims (1)
ロヘキシル基、シクロヘプチル基、シクロオクチル基、
シクロノニル基、シクロデシル基、シクロドデシル基又
はフェニル基を意味し、該シクロブチル基、シクロペン
チル基、シクロヘキシル基、シクロヘプチル基、シクロ
オクチル基、シクロノニル基、シクロデシル基、シクロ
ドデシル基及びフェニル基はハロゲン原子を一つ以上有
してもよく、Xはメチレン、エチレン、プロピレン、ブ
チレンを意味する)で示される化合物及びその塩1. A general formula (In the formula, R is a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group,
A cyclononyl group, a cyclodecyl group, a cyclododecyl group or a phenyl group means a cyclohexyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, a cyclodecyl group, a cyclododecyl group or a phenyl group and a halogen atom. One or more, and X represents methylene, ethylene, propylene, butylene) and a salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62047392A JPH0774218B2 (en) | 1987-03-02 | 1987-03-02 | Benzopyranotriazole derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62047392A JPH0774218B2 (en) | 1987-03-02 | 1987-03-02 | Benzopyranotriazole derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63215680A JPS63215680A (en) | 1988-09-08 |
| JPH0774218B2 true JPH0774218B2 (en) | 1995-08-09 |
Family
ID=12773839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62047392A Expired - Fee Related JPH0774218B2 (en) | 1987-03-02 | 1987-03-02 | Benzopyranotriazole derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0774218B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6866583B2 (en) * | 2016-07-05 | 2021-04-28 | Dic株式会社 | Liquid crystal compound |
| SG11202012930RA (en) | 2018-07-06 | 2021-01-28 | Orfan Biotech Inc | Triazole glycolate oxidase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5519292A (en) * | 1978-07-24 | 1980-02-09 | Beecham Group Ltd | Benzopyranotriazoles*their manufacture and medical composition containing them |
| EP0032821B1 (en) * | 1980-01-19 | 1985-04-10 | Beecham Group Plc | Substituted benzopyranotriazoles |
| JPS57128668A (en) * | 1981-02-02 | 1982-08-10 | Chisso Corp | 4-alkoxyphenylpropiolic acid 4'-cyanophenyl ester |
-
1987
- 1987-03-02 JP JP62047392A patent/JPH0774218B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63215680A (en) | 1988-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0164593B1 (en) | Anti-inflammatory phthalazinones | |
| KR880001374B1 (en) | Process for preparing 2-pheno yalkyl-1,2,4-triazol-3 one antidepressants | |
| DE69723846T2 (en) | Process for the preparation of sildenafil | |
| FR2643903A1 (en) | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS | |
| US4074048A (en) | Process for the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides | |
| SK279474B6 (en) | SUBSTITUTED N- (ARYLOXYALKYL) HETEROARYLPIPERIDINE | |
| JPH0625134B2 (en) | New heterocyclic compound | |
| JPS59161346A (en) | Manufacture of phenol derivative | |
| JP4704353B2 (en) | Quinoline carboxylic acid compound having 5-HT4 receptor agonist activity | |
| SU585811A3 (en) | Method of preparing benzimidazolinone derivatives or salts thereof | |
| JPS6124589A (en) | Novel compound, manufacture and medicinal composition | |
| JPS5824585A (en) | Novel theophylline derivative and manufacture | |
| PL106076B1 (en) | METHOD OF MAKING NEW THENOTHIAZINE DERIVATIVES | |
| JPH0774218B2 (en) | Benzopyranotriazole derivative | |
| SU1340585A3 (en) | Method of producing derivatives of tetrazole | |
| US3530137A (en) | Certain alkyl and aryl ethers and thioethers of tropine and derivatives thereof | |
| JPH01156966A (en) | Pyridazinone, triazinone and oxapyridazinone compounds having lipoxygenase inhibiting action | |
| US4090020A (en) | Thienothiazine derivatives | |
| CA1318676C (en) | Benzimidazole derivatives and process for their preparations | |
| US4590192A (en) | Benzisothiazoles, their pharmaceutical compositions, and method of use | |
| US4175085A (en) | Thienothiazine derivatives | |
| JPH03215488A (en) | Pyrimidobenzimidazole derivative | |
| JP2690742B2 (en) | Heterocyclic amine derivative | |
| JPH0174A (en) | Benzimidazole derivatives | |
| BE660853A (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |